FDA Review Of Byetta Monotherapy Heads Into 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin/Lilly say FDA is unlikely to complete a review of the diabetes application by the end of the year, as previously anticipated.
You may also be interested in...
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.
Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
Label with expanded language about thyroid cancer risk is expected.